on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Achieves High Warrant Exercise Rate
Onco-Innovations Limited, a Vancouver-based company, announced that over 90% of its outstanding common share purchase warrants priced at $0.60 have been exercised. This significant milestone was reached over an eight-month period, enhancing the company's capital inflow and demonstrating the success of its internal financing strategy.
The company highlighted that this warrants exercise aligns with its non-dilutive financing goals. The high conversion rate indicates strong shareholder support and confidence in Onco-Innovations' long-term vision, according to Thomas O'Shaughnessy, the CEO.
These developments affirm Onco-Innovations' strategic direction as it continues its focus on innovative cancer research and treatment solutions.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news